Category: Finance
-
Asthma/COPD Device Maker Lands $14.5M in Venture Funds
5 September 2014. Propeller Health in Madison, Wisconsin, developer of a system to track respiratory disorder medications in real time, secured $14.5 million in its second round of venture financing. The funding round was led by venture investment company Safeguard Scientifics, with participation by the Social+Capital Partnership, Propeller Health’s previous funding source. The Propeller Health…
-
Trial Crowdsources Lung Cancer Biomarker Screening
22 August 2014. A clinical trial at University of Colorado Cancer Center in Aurora is recruiting participants through an online campaign to find people with lung cancer that meet a specific genetic profile who would most likely respond to the drug being tested. The study is led by Ross Camidge, director of the center’s thoracic…
-
New Medical Technologies Investment Fund Raises $110M
19 August 2014. HealthQuest Capital, a spin-off investment firm, says it raised $110 million for funding in technology-based start-ups serving the health care industry. The company was spun off from Sofinnova Ventures in Menlo Park, California and founded by Garheng Kong, a Sofinnova general partner. HealthQuest plans to invest in companies developing medical devices, diagnostics, patient-care…
-
Novartis Acquires Stake in Stem Cell Therapy Company
19 August 2014. Gamida Cell, a developer of therapies from umbilical cord stem cells, says the global pharmaceutical company Novartis is buying a 15 percent interest in the company, with an option to acquire the entire company later. The deal brings Gamida Cell, located in Jerusalem, Israel, $35 million immediately, with a total potential return…
-
$500K Challenge Seeks Techniques to Track Single Cells
18 August 2014. A new challenge sponsored by National Institutes of Health is looking for better ways to follow and predict the functioning of a single cell in a complex multi-cell environment, such as in a tumor or a response to treatment. The competition, managed by the open-innovation/challenge company InnoCentive, expects to award prizes totaling…
-
Middle, Inner Ear Drug Developer Raises $100M in IPO
13 August 2014. Otonomy Inc., a biopharmaceutical company in San Diego developing treatments for disorders of the middle and inner ear, raised $100 million in its initial public offering of stock. The company, trading on the NASDAQ under the symbol OTIC, priced its 6.25 million shares at $16.00. Otonomy was founded in 2008 by physicians…
-
Heart Assn Challenge Seeks Heart Disease Prevention Tools
11 August 2014. American Heart Association seeks new products to better prevent and manage heart disease and stroke in an open-innovation challenge for early-stage companies in the Midwest. The top three winners will be eligible for awards of up to $20,000, and a chance to pitch their ideas at a November forum on health care…
-
Immunotherapy Start-Up Adds $134M in Venture Funding
5 August 2014. Juno Therapeutics, a biotechnology company in Seattle developing cancer treatments that harness the human immune system, secured $134 million in its second round of venture financing. The company, a spin-off enterprise from research labs in Seattle and New York, says the new round was provided by 10 public mutual funds and health…
-
Roche Acquiring RNA Medications Biotech Company
5 August 2014. The pharmaceutical company Roche is acquiring Santaris Pharma, a biotechnology company developing therapies targeting ribonucleic acid or RNA that performs vital genetic functions. Roche is expected to pay as much as $450 million for Santaris, based in Hørsholm, Denmark. Santaris designs therapies focusing on RNA, a fundamental molecular building block in the…
-
Allied Minds, Bristol-Myers Squibb Form Life Science Venture
4 August 2014. Allied Minds, a research commercialization company in Boston, and the pharmaceutical company Bristol-Myers Squibb in New York are starting a joint venture to discover new drug candidates and enterprises from promising life science research in U.S. university labs. Financial terms of the new venture, named Allied-Bristol Life Sciences LLC, were not disclosed.…